tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk 🚨 Breaking News: Real-World Data

I atrophied a lot when using it And another commenter had this to say: I did try Ozempic

Conflict of interest FG has received research support from Eli Lilly, Lifescan, and Takeda, and has provided advisory services to AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi

Accessing GLP-1 Therapy Without Breaking Your Budget The total monthly investment for sustainable weight loss through PlexusDx ranges from $129/mo to $349/mo depending on the formulation selected, compared to the $900$1,500 patients typically pay for brand-name GLP-1 injections

After this initial month, it is recommended to increase the dose to 7 mg of Rybelsus once daily3

The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone

Five patients were on dialysis and one had stage 5 chronic kidney disease